Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 13 of the 34 sources its claims cite were checked for support.
Abstract
Both apixaban and rivaroxaban have been approved for use in acute venous thromboembolism (VTE). Although indirect comparison through network meta-analyses of randomized trials have been performed to compare the efficacy and safety of these agents, further comparison between these agents was lacking until recently. We sought to systematically review and carry out a meta-analysis of studies to further compare apixaban with rivaroxaban from multiple studies done in the real-world settings. Studies comparing rivaroxaban with apixaban in patients with acute VTE were identified through electronic literature searches of MEDLINE, EMBASE, Scopus, and the Cochrane library up to May 2019. Study-specific risk ratios (RRs) were calculated and combined using a random-effects model meta-analysis. In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45). Clinically relevant major bleeding occurred in 85 of 11 559 patients (0.74%) in the apixaban group and 350 of 33 909 patients (1.03%) in the rivaroxaban group (RR, 0.73; 95% CI, 0.58-0.93; P = .01). Clinically relevant nonmajor bleeding occurred in 169 of 3417 patients (4.95%) in the apixaban group and 1094 of 12 475 patients (8.77%) in the rivaroxaban group (RR, 0.59; 95% CI, 0.50-0.70; P < .01). Apixaban shows equivalent efficacy in prevention of recurrent VTE but decreased risk of major and minor bleeding events compared with rivaroxaban.
Overview
CoChat Summary
TL;DR
This real-world systematic review and meta-analysis found that apixaban and rivaroxaban had similar efficacy for preventing recurrent VTE in acute VTE, but apixaban had lower bleeding risk. Across 5 studies and 45,468 patients, major and minor bleeding were significantly less frequent with apixaban.
Key findings
- The review included 5 studies with a total of 45,468 patients analyzed for recurrent VTE and bleeding outcomes.
- For recurrent VTE up to 6 months, there was no significant difference between apixaban and rivaroxaban: 1.14% vs 1.35%; RR 0.89 (95% CI 0.67-1.19; P = .45).
- Clinically relevant major bleeding was lower with apixaban: 0.74% vs 1.03%; RR 0.73 (95% CI 0.58-0.93; P = .01).
- Clinically relevant nonmajor bleeding was also lower with apixaban: 4.95% vs 8.77%; RR 0.59 (95% CI 0.50-0.70; P < .01). The paper also reports a composite of major and minor bleeding of 5.56% vs 9.51%; RR 0.60 (95% CI 0.52-0.70).
Methods
- PRISMA-guided systematic review of studies published from database inception to May 2019, searching MEDLINE, Cochrane Library, EMBASE, and conference abstracts; no language restriction.
- Included human studies with acute VTE that directly compared apixaban vs rivaroxaban and reported VTE or bleeding outcomes up to 3 months minimum; studies with AF-only populations or indirect comparisons to warfarin/LMWH were excluded.
- Outcomes were pooled using a random-effects meta-analysis in RevMan 5.3, reporting risk ratios (RRs) and 95% CIs; heterogeneity was assessed with I².
Limitations
- The paper states that the included studies were nonrandomized, so unaccountable confounders may remain despite attempts to reduce confounding.
- It also states that doses and compliance could not be determined from the database/registry studies, and that intracranial bleeding, gastrointestinal bleeding, cardiac bleeding, and mortality were inconsistently reported.
- Evident from the text: the evidence base was small (5 studies) and follow-up was limited to about 6 months, so longer-term comparative effects are not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 2 Not valid · 10 Not checked · 31 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Various retrospective studies (database, registries) have been carried out looking at head-to-head comparisons between apixaban and rivaroxaban on VTE recurrence risk and bleeding risk. 8-11”
What the sources say
- Supportedcites [8] Sindet-Pedersen, 2018, Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study, Eur Heart J Cardiovasc Pharmacother source
The Conclusion identifies this as an observational head-to-head comparison of apixaban and rivaroxaban in patients with VTE, examining recurrent VTE and bleeding. The Data sources and Ethics sections describe its use of Danish administrative registries and identify the design as retrospective. This paper therefore supports the citation as an example of the studies described; page numbers were not supplied. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [9] Bott-Kitslaar, 2019, Apixaban and rivaroxaban in patients with acute venous thromboembolism, Mayo Clin Proc source
- Not checked — no full text of the sourcecites [10] Dawwas, 2019, Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis, Lancet Haematol source
- Not checked — no full text of the sourcecites [11] Howe, 2019, Bleeding rates of veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism, J Thromb Thrombolysis source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hence, the more favorable bleeding profile is proposed to be a result of the decreased peak-to-trough ratios afforded by twice-daily DOAC dosing. 19”
What the sources say
- Partly supportedcites [19] Frost, 2013, Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects, Br J Clin Pharmacol sourceExperimental — accuracy not yet measured
The Pharmacokinetics section reports a lower peak-to-trough ratio with twice-daily than once-daily apixaban dosing. But the Discussion says there is no definitive evidence that this difference provides a benefit, and the paper does not propose it as an explanation for a more favorable bleeding profile. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The study by Lutsey et al was included only for major bleeding outcome because the VTE events and minor bleeding events were not recorded. 14”
What the sources say
- Partly supportedcites [14] Lutsey, 2019, Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism, Br J Haematol sourceExperimental — accuracy not yet measured
The Introduction and Methods (Identification of hospitalised bleeding events) show that the study evaluated major hospitalised bleeding, not minor bleeding or recurrent VTE as outcomes. But Methods (Study population) explicitly records initial VTE events, so the statement that VTE events were not recorded is too broad. The paper also does not establish that the unavailability of those outcomes was the citing authors’ reason for including the study only for major bleeding. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“At the same time, the presence of unaccountable confounders must be considered when interpreting our results, especially in light of the nonrandomized designs, despite various analyses performed in the included studies to reduce the confounders. 20”
What the sources say
- Supportedcites [20] Proietti, 2018, Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis, Stroke source
The Limitations section says that, because the review is based on real-world studies, unaccountable confounders must be considered when interpreting its results. The Discussion identifies the reported studies as observational and warns of residual confounding; the Study Characteristics section also identifies a propensity-score-matched comparison. Page numbers are unavailable in our copy. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 3 studies involving 24 041 patients, recurrent VTE up to 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% CI, 0.67-1.19; P 5 .45; I 2 5 0%) (Figure 2).”
plainn = 24,041- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
25 more claims
Create a free account to see all 53 claims and every source verdict.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 11
Citations
Cites
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 807
PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts
Beller, E. M., Glasziou, P. P., Altman, D. G., Hopewell, S., Bastian, H., Chalmers, I., Gøtzsche, P. C., Lasserson, T., Tovey, D., & for the PRISMA for Abstracts Group (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001419 · Cited by 706 · cited 1×
“Methods The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement for reporting systematic reviews as recommended by the Cochrane Collaboration was used for this systematic review.(13) This qualitative systematic review included studies published from database inception up to May 2019.”
MethodNational trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286 · cited 1×
“Hence, the more favorable bleeding profile is proposed to be a result of the decreased peak-to-trough ratios afforded by twice-daily DOAC dosing.(19) Strengths and limitations This meta-analysis compared apixaban “directly” short of head-tohead RCT to rivaroxaban and included a large patient sample that was representa…”
BackgroundRay, W. A., Chung, C. P., Murray, K. T., Smalley, W. E., Daugherty, J. R., Dupont, W. D., & Stein, C. M. (2018) · JAMA · doi:10.1001/jama.2018.17242 · Cited by 222
Shah, S., Norby, F. L., Datta, Y. H., Lutsey, P. L., MacLehose, R. F., Chen, L. Y., & Alonso, A. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017010694 · Cited by 173
Proietti, M., Romanazzi, I., Romiti, G. F., Farcomeni, A., & Lip, G. Y. H. (2018) · Stroke · doi:10.1161/strokeaha.117.018395 · Cited by 126
Direct oral anticoagulants: analysis of worldwide use and popularity using Google trends
Lippi, G., Mattiuzzi, C., Cervellin, G., & Favaloro, E. J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.65 · Cited by 91 · cited 1×
“Lead-in anticoagulation with heparin products adds complexity to the treatment regimen and is 1 reason why dabigatran or edoxaban is less often prescribed than apixaban and rivaroxaban.(2) Hence, apixaban and rivaroxaban are now increasingly used for acute VTE compared with VKAs and other DOACs.”
BackgroundManzoor, B. S., Lee, T. A., Sharp, L. K., Walton, S. M., Galanter, W. L., & Nutescu, E. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1989 · Cited by 88
Cited by
Ballestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 146
“acute VTE have shown that apixaban had a significantly lower risk of major and minor bleeding events than rivaroxaban, with equivalent efficacy in prevention of recurrent VTE events [33, 34].”
BackgroundDawwas, G. K., Leonard, C. E., Lewis, J. D., & Cuker, A. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0717 · Cited by 83
A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
Wong, D. J., Park, D., Park, S. J., Haller, C. A., Chen, J., Dai, E., Liu, L., Mandhapati, A. R., Eradi, P., Dhakal, B., et al. (2021) · Blood · doi:10.1182/blood.2020009428 · Cited by 58
Recommendations for VTE Prophylaxis in Medically Ill Patients
Skeik, N., & Westergard, E. (2020) · Annals of Vascular Diseases · doi:10.3400/avd.ra.19-00115 · Cited by 59
Deng, K., Cheng, J., Rao, S., Xu, H., Li, L., & Gao, Y. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00107 · Cited by 42
Metadata
- Authors
- Aryal, M. R., Gosain, R., Donato, A., Yu, H., Katel, A., Bhandari, Y., Dhital, R., & Kouides, P. A.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- Reading Hospital (US)
- Kathmandu University (NP)
- University at Buffalo, State University of New York (US)
- Unity Health System (US)
- Corresponding author
- Aryal, Madan Raj
- Gosain, Rohit
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2019-08-12
- Volume
- 3
- Issue
- 15
- Pages
- 2381-2387
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC6693001
- OpenAlex
- W2968913818
- Semantic Scholar
- 94cd554c2737a89391de9b6c4e066ef7bc43e6d9
- Cited by
- 62
- References
- 19
- Citations by year
- 2026: 11 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 16 · 2021: 7 · 2020: 11 · 2019: 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- apixaban, rivaroxaban, venous thromboembolism, recurrent venous thromboembolism, major bleeding, direct oral anticoagulants, real-world evidence, anticoagulant efficacy and safety
- MeSH terms
- Rivaroxaban, Blood Coagulation, Hemorrhage, Humans, Pyrazoles, Pyridones, Odds Ratio, Treatment Outcome, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000572
- The paper
- Aryal, M. R., Gosain, R., Donato, A., Yu, H., Katel, A., Bhandari, Y., Dhital, R., & Kouides, P. A. (2019). Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.